ClinicalTrials.gg
TerminatedNCT04975256Updated Dec 16, 2024

Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)

A Phase 1 interventional study of MRTX849 and BI 1701963 in Advanced Cancer, Metastatic Cancer and Malignant Neoplasm of Colon, sponsored by Mirati Therapeutics Inc.. Terminated at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-16.

Sponsored by Mirati Therapeutics Inc. (part of Bristol-Myers Squibb) · Phase 1, Interventional, and Treatment

Why this study was terminated
The decision was made to terminate this study to further enrollment, as of 08 March 2022. The decision was made primarily due to a change in development strategy.

From the registry’s dates

  • Primary completion was Nov 2022, 4 years ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
7
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 50 studies in Neoplasm Metastasis by Bristol-Myers Squibb — 1 open to participants now, 8 under way, 1 of them phase 3. Neoplasm Metastasis · Bristol-Myers Squibb.

Enrollment
41st of 44
7 · median 66
Started
2021
with 3 others
Phase 1
16 of 50
none open now
Registered
39th of 50
by date

Among the 50 studies in Neoplasm Metastasis by Bristol-Myers Squibb, this one is the 41st largest by enrollment of the 44 interventional ones that give a count, is one of 4 that started in 2021, is one of 16 in phase 1, and was the 39th registered.

Neoplasm Metastasis

4,046 studies on the registry are indexed under Neoplasm Metastasis; 889 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

1 of the 50 studies in Neoplasm Metastasis by Bristol-Myers Squibb is open now, in 11 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 690 Neoplasm Metastasis studies recruiting now, 537 (78%) set no upper age limit and 97 (14%) stop at 75 or younger; 48 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies in Neoplasm Metastasis by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

This study will evaluate safety, tolerability, drug levels, molecular effects and clinical activity of MRTX849 (adagrasib) in combination with BI 1701963 in patients with advanced solid tumors that have a KRAS G12C mutation.

Read the detailed description

This study will evaluate safety, tolerability, pharmacokinetics, metabolites, pharmacodynamics and clinical activity of MRTX849 (adagrasib) in combination with BI 1701963 in patients with advanced solid tumors with a KRAS G12C mutation. MRTX849 is an orally available small molecule inhibitor of KRAS G12C and BI 1701963 is a SOS1 pan-KRAS inhibitor.

03

Conditions studied

  • Advanced Cancer
  • Metastatic Cancer
  • Malignant Neoplasm of Colon
  • Malignant Neoplasm of Lung
  • Malignant Neoplastic Disease

Keywords

  • KRAS G12C
  • SOS1 Inhibitor
  • NSCLC
  • CRC
  • Non Small Cell Lung Cancer
  • Colon Cancer
  • Advanced Solid Tumor
  • Metastatic Cancer
  • Pancreatic Cancer
  • adagrasib
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed diagnosis of a solid tumor with KRAS G12C mutation (phase 1b must be either Non-Small Cell Lung Cancer or Colorectal Cancer)
  • Unresectable or disease
  • No available treatment with curative intent
  • Adequate organ function

Exclusion criteria

Exclusion Criteria:

  • History of intestinal disease, inflammatory bowel disease, major gastric surgery, or other gastrointestinal conditions likely to alter absorption of study treatment or result in inability to swallow
  • Other active cancer
  • Cardiac abnormalities
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
7 participants (actual)

Study arms

  • Experimental
    Dose escalation

    Dose escalation of MRTX849 and BI 1701963 to determine maximum tolerated dose in combination

    Drug: MRTX849 · Drug: BI 1701963

  • Experimental
    Dose expansion

    Expansion cohorts in NSCLC and CRC patients to ensure sufficient safety experience, pharmacokinetic information, and early evidence of clinical activity of MRTX849 in combination with BI 1701963

    Drug: MRTX849 · Drug: BI 1701963

Interventions

  • KRAS G12C inhibitor

    Also known as: KRAS G12C inhibitor, adagrasib

  • SOS1 Inhibitor

    Also known as: SOS1 Inhibitor

06

What researchers measure

Primary outcomes

  1. Characterize the number of patients with treatment emergent adverse events of the combination regimen in patients with advanced solid tumor malignancies with KRAS G12C mutation

    Number of participants with treatment related adverse events

    Time frame: 20 months

  2. Evaluate Pharmacokinetics of the combination regimen

    Blood plasma concentration

    Time frame: 20 months

  3. Establish Maximum Tolerated Dose

    Number of patients with dose limiting toxicity

    Time frame: 12 months

Secondary outcomes

  1. Evaluate preliminary clinical activity of the combination regimen

    Objective response rate in accordance with Response Evaluation Criteria in Solid Tumors (RECIST)

    Time frame: 20 months

07

Study locations

4 sites
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • The Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Next Oncology
    San Antonio, Texas 78229, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2021 to primary completion in Nov 2022, 15 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2021
First posted
Jul 23, 2021
StartActual
Jul 28, 2021
Primary completionActual
Nov 2, 2022
CompletionActual
Nov 15, 2022
Last update
Dec 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04975256
Responsible party
Sponsor
First posted
Jul 23, 2021
Start date
Jul 28, 2021
Primary completion
Nov 2, 2022
Completion
Nov 15, 2022
Last update
Dec 16, 2024

Study contacts

Richard Chao, MD
study director · Mirati Therapeutics

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Adagrasib · Pan-KRAS Inhibitor BI 1701963

Start the discussion